RCS - MicroSalt PLC - Patent Issuance for Novel Low Sodium Salt

MicroSaltAnnouncement

15/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240515:nRSO4438Oa&default-theme=true

RNS Number : 4438O  MicroSalt PLC  15 May 2024

 

15 May 2024

MicroSalt plc

("MicroSalt" or the "Company")

 

Patent Issuance for Novel Low Sodium Salt

 

MicroSalt plc, (AIM: SALT) a company producing full-flavour, low-sodium salt
for food manufacturers and consumers, is pleased to announce that the United
States Patent and Trademark Office has granted and will issue its patent
number 11,992,034 entitled Low Sodium Salt Composition on 28 May 2024 (the
"Patent"). This relates to Microsalt's patent application No. 18/175,028,
previously announced by the Company on 6 March 2024.

 

The Patent concerns the production of MicroSalt having claims directed to a
low-sodium salt that adheres better to foods than a traditional salt that is
not adhered to a carrier particle, and that is produced according to
MicroSalt's claimed improved production process.

 

MicroSalt also has counterpart patent applications as described in the
Company's admission document dated 27 January 2024, with claims directed to
similar subject matter as the Patent, pending in countries including China,
Chile, Australia, Brazil, Europe, Canada, Japan, Russia, Mexico, India and
Hong Kong.

 

MicroSalt also owns a previously issued United States patent directed to its
salt carrier product and production processes, and a United States provisional
patent application directed to additional innovations.

 

Rick Guiney, CEO of Microsalt, said:

 

"We believe the grant of patent 11,992,034 is an important milestone for the
Company as it further strengthens our IP position in the global low sodium
market."

 

 For more information, please visit www.microsaltinc.co
(http://www.microsaltinc.co) , follow on X @microSaltPLC or contact:

 

 MicroSalt plc                                                                                            Via Flagstaff
 Rick Guiney, CEO

 Zeus (Nominated Adviser and                                                         +44 (0)20 3829 5000
 Broker)

 David Foreman / James Edis (Investment Banking)

 Dom King (Corporate Broking), Rupert Woolfenden (Sales)

 Flagstaff PR (Financial IR/FPR)                                                                          +44 (0)20 7129 1474
 Tim Thompson / Alison Allfrey / Anna Probert

 microsalt@flagstaffcomms.com

 

 

Notes to Editors

 

MicroSalt® produces a patented full-flavour, low-sodium salt for food
manufacturers and consumers.

 

MicroSalt is a major potential disruptor in the food market, thanks to its
micron sized particles which deliver the same sense of saltiness to a wide
range of foods but with approximately 50% less sodium. Excess sodium
consumption is a significant contributor to cardiovascular disease and
MicroSalt's solution meets the rising demand for healthier alternatives to
traditional salt. The WHO has set a target for reducing global sodium intake
by 30% by 2025, which it estimates will save 7 million lives by 2030.

 

Each year, cardiovascular disease costs the UK £19 billion - if the average
salt intake was reduced by one gram per day, it has been estimated that 4,147
lives and £288 million would be saved each year in the UK. As a nation, the
UK consumes 183 million kilograms of salt each year, and 70% of the typical
person's sodium intake is hidden in processed foods.

 

Operational since 2018, MicroSalt uses a patent-protected technology which
helps create high barriers to entry within the reduced-sodium salt market.

 

The Directors believe that MicroSalt is well positioned to capture growth in
the low sodium market, which is expected to grow exponentially, and that there
is also scope to enter the larger salt market.

 

ENDS

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFIAESISLIS